On Tuesday, Truist Securities began coverage on shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA), issuing a Buy rating and setting a price target of $25.00. The announcement from ...

On Tuesday, May 27, an analyst from Truist Securities initiated coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $25. Teva Pharma is an ...

On Tuesday, Truist Securities began coverage on shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA), issuing a Buy rating and setting a price target of $25.00. The announcement from Truist ...

The $25 price target represents Truist’s valuation of Teva Pharma’s stock, factoring in the company’s market performance and future growth expectations.

On Friday, Goldman Sachs (NYSE: GS) analysts initiated coverage on Teva Pharmaceutical Industries Ltd. (NYSE: NYSE: TEVA) with a Buy rating and set a price target of $24.00. The analysts highlighted ...

By 2030, Teva now expects to achieve at least $5 billion in innovative medicine sales, driven largely by Austedo, Ajovy and Uzedy.

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its ...

While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation (MFN) drug pricing has weighed heavily on the pharmaceutical industry in recent months, many ...

There's an unofficial Teva sale happening this weekend. Save up to 40% on sandals for hiking, water activities and camping.